A new paradigm for navigating compound property related drug attrition

Drug Discovery Today

Volumn 21, Issue 1, 2016, Pages 72-81

  Barton, Patrick ^a   Riley, Robert J ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b EVOTEC UK LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; AMPRENAVIR; ATAZANAVIR; ATORVASTATIN; BOSENTAN; CERIVASTATIN; DARUNAVIR; FLUINDOSTATIN; INDINAVIR; LOPINAVIR; MACITENTAN; MULTIDRUG RESISTANCE PROTEIN 1; NELFINAVIR; PRAVASTATIN; RITONAVIR; ROSUVASTATIN; SAQUINAVIR; SITAXSENTAN; TIPRANAVIR; DRUG;

CELL MEMBRANE PERMEABILITY; CLASSIFICATION; DRUG DEVELOPMENT; DRUG DISPOSITION; DRUG INDUSTRY; DRUG SOLUBILITY; DRUG TRANSPORT; ENTHALPY; LIPOPHILICITY; LIVER TOXICITY; PHYSICAL CHEMISTRY; REVIEW; CHEMISTRY; DRUG INTERACTION; HUMAN; PHYSIOLOGY; PROCEDURES; TRANSPORT AT THE CELLULAR LEVEL;

BIOLOGICAL TRANSPORT; DRUG DISCOVERY; DRUG INTERACTIONS; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 84960459073     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2015.09.010     Document Type: Review

References (63)

1. I. Kola, and J. Landis Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3 2004 711 716
2. P.D. Leeson, and S.A. St-Gallay The influence of the 'organizational factor' on compound quality in drug discovery Nat. Rev. Drug Discov. 10 2011 749 765
3. S.M. Paul, and et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214
4. D.C. Swinney, and J. Anthony How were new medicines discovered? Nat. Rev. Drug Discov. 10 2011 507 519
5. M.M. Hann, and G.M. Keserü Finding the sweet spot: the role of nature and nurture in medicinal chemistry Nat. Rev. Drug Discov. 11 2012 355 365
6. C. Springer, and K.L. Sokolnicki A fingerprint pair analysis of hERG inhibition data Chem. Cent. J. 7 2013 167
7. M.J. Waring, and C. Johnstone A quantitative assessment of hERG liability as a function of lipophilicity Bioorg. Med. Chem. Lett. 17 2007 1759 1764
8. U.M. Hanumegowda, and et al. Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds Chem. Res. Toxicol. 23 2010 749 755
9. R.J. Riley, and et al. Time-dependent CYP inhibition Expert Opin. Drug Metab. Toxicol. 3 2007 51 66
10. A. Srivastava, and et al. Identification and mitigation of a reactive metabolite liability associated with aminoimidazoles Chem. Res. Toxicol. 27 2014 1586 1597
11. D.J. Warner, and et al. Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification Drug Metab. Dispos. 40 2012 2332 2341
12. L. Harnisch, and et al. Modeling and simulation as a tool to bridge efficacy and safety data in special populations CPT Pharmacometrics Syst. Pharmacol. 2 2013 e28
13. P. Morgan, and et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival Drug Discov. Today 17 2012 419 424
14. K.H. Grime, and et al. Application of in silico, in vitro and preclinical pharmacokinetic data for the effective and efficient prediction of human pharmacokinetics Mol. Pharm. 10 2013 1191 1206
15. D.F. Veber, and et al. Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 45 2002 2615 2623
16. M.J. Waring Defining optimum lipophilicity and molecular weight ranges for drug candidates - molecular weight dependent lower logD limits based on permeability Bioorg. Med. Chem. Lett. 19 2009 2844 2851
17. C.A. Lipinski Lead- and drug-like compounds: the rule-of-five revolution Drug Discov. Today Technol. 1 2004 337 341
18. P.D. Leeson, and A.M. Davis Time-related differences in the physical property profiles of oral drugs J. Med. Chem. 47 2004 6338 6348
19. M.C. Wenlock, and et al. A comparison of physiochemical property profiles of development and marketed oral drugs J. Med. Chem. 46 2003 1250 1256
20. C.A. Lipinski, and et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 23 1997 3 25
21. J. Petit, and et al. Softening the Rule of Five - where to draw the line? Bioorg. Med. Chem. 20 2012 5343 5351
22. B.C. Doak, and et al. Oral druggable space beyond the rule of 5: insights from drugs and clinical candidates Chem. Biol. 21 2014 1115 1142
23. M.P. Gleeson Generation of a set of simple, interpretable ADMET rules of thumb J. Med. Chem. 51 2008 817 834
24. H. Jhoti, and et al. The 'Rule of Three' for fragment-based drug discovery: where are we now? Nat. Rev. Drug Discov. 12 2013 644
25. G.R. Bickerton, and et al. Quantifying the chemical beauty of drugs Nat. Chem. 4 2012 90 98
26. M.C. Wenlock, and L.A. Carlsson How experimental errors influence drug metabolism and pharmacokinetic QSAR/QSPR models J. Chem. Inf. Model. 55 2015 125 134
27. M.D. Segall Multi-parameter optimization: identifying high quality compounds with a balance of properties Curr. Pharm. Des. 18 2012 1292 1310
28. M. Segall, and et al. Applying medicinal chemistry transformations and multiparameter optimization to guide the search for high-quality leads and candidates J. Chem. Inf. Model. 51 2011 2967 2976
29. T. Ryckmans, and et al. Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: a lipophilic efficiency (LipE) analysis Bioorg. Med. Chem. Lett. 19 2009 4406 4409
30. P.D. Leeson, and B. Springthorpe The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discov. 6 2007 881 890
31. G.A. Holdgate, and A.L. Gill Kinetic efficiency: the missing metric for enhancing compound quality? Drug Discov. Today 16 2011 910 913
32. R. Morphy The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds J. Med. Chem. 49 2006 2969 2978
33. K. Beaumont, and et al. Oral delivery of G protein-coupled receptor modulators: an explanation for the observed class difference Bioorg. Med. Chem. Lett. 15 2005 3658 3664
34. P.J. Conn, and et al. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders Nat. Rev. Drug Discov. 8 2009 41 54
35. S.M. DeWire, and et al. Beta-arrestins and cell signaling Annu. Rev. Physiol. 69 2007 483 510
36. J.D. Hughes, and et al. Physiochemical drug properties associated with in vivo toxicological outcomes Bioorg. Med. Chem. Lett. 18 2008 4872 4875
37. T. Grabowski, and et al. Correlations between no observed effect level and selected parameters of the chemical structure for veterinary drugs Toxicol. In Vitro 24 2010 953 959
38. D. Muthas, and et al. A critical assessment of modeling safety-related drug attrition MedChemComm 4 2013 1058 1065
39. T. Kogej, and et al. Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case Drug Discov. Today 18 2013 1014 1024
40. T.T. Wager, and et al. Improving the odds of success in drug discovery: choosing the best compounds for in vivo toxicology studies J. Med. Chem. 56 2013 9771 9779
41. C.Y. Wu, and L.Z. Benet Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system Pharm. Res. 22 2005 11 23
42. L.Z. Benet, and et al. BDDCS applied to over 900 drugs AAPS J. 13 2011 519 547
43. J.R. Landis, and G.G. Koch The measurement of observer agreement for categorical data Biometrics 33 1977 159 174
44. M.V. Varma, and et al. Physicochemical property space of hepatobiliary transport and computational models for predicting rat biliary excretion Drug Metab. Dispos. 40 2012 1527 1537
45. M. Tu, and et al. Medicinal chemistry design principles for liver targeting through OATP transporters Curr. Top. Med. Chem. 13 2013 857 866
46. Y. Shitara, and et al. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption Biopharm. Drug Dispos. 34 2013 45 78
47. M. Karlgren, and et al. Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions J. Med. Chem. 55 2012 4740 4763
48. C.W. Murray, and et al. Validity of ligand efficiency metrics ACS Med. Chem. Lett. 5 2014 616 618
49. C. Abad-Zapatero, and J.T. Metz Ligand efficiency indices as guideposts for drug discovery Drug Discov. Today 10 2005 464 469
50. D.E. Clark Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration J. Pharm. Sci. 88 1999 815 821
51. C. Chang, and et al. Pharmacophore-based discovery of ligands for drug transporters Adv. Drug Deliv. Rev. 58 2006 1431 1450
52. A. Toulmin, and et al. Toward prediction of alkane/water partition coefficients J. Med. Chem. 51 2008 3720 3730
53. T.J. Ritchie, and S.J. Macdonald How drug-like are 'ugly' drugs: do drug-likeness metrics predict ADME behaviour in humans? Drug Discov. Today 19 2014 489 495
54. H.A. Zhong, and et al. Understanding the molecular properties and metabolism of top prescribed drugs Curr. Top. Med. Chem. 13 2013 1290 1307
55. International Transporter Consortium Membrane transporters in drug development Nat. Rev. Drug Discov. 9 2010 215 236
56. N.A. Meanwell Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety Chem. Res. Toxicol. 24 2011 1420 1456
57. M. Chen, and et al. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury Hepatology 58 2013 388 396
58. S. Nakayama, and et al. A zone classification system for risk assessment of idiosyncratic drug toxicity using daily dose and covalent binding Drug Metab. Dispos. 37 2009 1970 1977
59. I.D. Kuntz, and et al. The maximal affinity of ligands Proc. Natl. Acad. Sci. U. S. A. 96 1999 9997 10002
60. M. Congreve, and et al. A 'Rule of Three' for fragment-based lead discovery? Drug Discov. Today 8 2003 876 877
61. G.M. Keseru, and G.M. Makara The influence of lead discovery strategies on the properties of drug candidates Nat. Rev. Drug Discov. 8 2009 203 212
62. S. Braggio, and et al. Drug efficiency: a new concept to guide lead optimization programs towards the selection of better clinical candidates Expert Opin. Drug Discov. 5 2010 609 618
63. A.L. Hopkins, G.M. Keserü, P.D. Leeson, D.C. Rees, and C.H. Reynolds The role of ligand efficiency metrics in drug discovery Nat. Rev. Drug Discov. 13 2014 105 121